PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact

Concerns Related to PEGylation Anti PEG Antibody .pdf

Original filename: Concerns Related to PEGylation Anti-PEG Antibody.pdf
Author: Administrator

This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 14/02/2020 at 07:56, from IP address 198.11.x.x. The current document download page has been viewed 66 times.
File size: 162 KB (3 pages).
Privacy: public file

Download original PDF file

Document preview


Biochempeg Scientific Inc.

Concerns Related to PEGylation: Anti-PEG Antibody
Biopharmaceuticals have become increasingly attractive therapeutic agents
and the PEGylation technology has brought more than a dozen protein
drugs to the market. Surface conjugation of PEG to proteins can prolong its
blood circulation time and reduce immunogenicity by increasing its
hydrodynamic size and masking surface epitopes.

Advantages of using PEGylation:
◆ Higher bioavailability

Improve the circulation of drugs in the blood


Optimal pharmacokinetics


Reduced immune response


Less administrations

Despite this success, emerging literature highlights the presence of antibodies
produced by the immune system that specifically recognize and bind to PEG
(anti-PEG Abs), including pre-existing and treatment-inducing antibodies. Over
the past few decades, free PEG has been used in a variety of applications


Biochempeg Scientific Inc.

such as osmotic laxatives, topical medications, cosmetics, and various other
household and consumer products. As a result, many patients have been
previously exposed to PEG, leading to detection of anti-PEG antibodies in
human blood prior to administration of the PEGylated drug / NP. More
importantly, in some clinical reports examining different PEGylated therapeutic
agents, the presence of anti-PEG Abs has been associated with a loss of
therapeutic efficacy and an increase in adverse reactions. Many studies have
shown that anti-PEG antibodies limit the activity of PEGylated drugs and may
compromise the activity of other effective therapeutic agents.

Image source: https://www.ncbi.nlm.nih.gov/
Therefore, the research community should develop strategies to overcome the
PEG-related immune response. Researchers have studied ways to overcome
the immunological problems of PEG using alternative hydrophilic polymers
instead of PEG. The researchers believe that these polymers can form
self-assembled nanoparticles and have less effective immunogenicity than
PEG. More specifically, the replacement hydrophilic polymer did not exhibit the


Biochempeg Scientific Inc.

ABC phenomenon after repeated administration. Therefore, novel hydrophilic
polymers other than PEG may have potential as drug delivery vehicles. On the
other hand, the absence of the observable ABC phenomenon does not mean
that there is no effective immunogenicity in these hydrophilic polymers.
Various synthetic polymers, as well as natural products, show
antibody-inducing effects. Therefore, researchers should conduct further and
accurate evaluations of the use of alternative hydrophilic polymers. We should
keep in mind that specific antibodies against each polymer need further
evaluation. Another way to solve the problem of PEG immunity is to use
immunosuppressive or immunosuppressive conditions to prevent
PEG-specific specific immune response pathways and adverse side effects.
This method can suppress the PEG-specific immune response. However, the
use of these agents may trigger side effects. How we specifically inhibit the
PEG-related immune response is a key issue that has been studied. In short,
completely suppressing the PEG-related immune response is still a difficult
challenge, and it is of great significance for the future design of drug carriers
and biopharmaceuticals.

Keywords: PEG (polyethylene glycol), PEGylation, hypersensitivity, anti-PEG

Concerns Related to PEGylation Anti-PEG Antibody.pdf - page 1/3
Concerns Related to PEGylation Anti-PEG Antibody.pdf - page 2/3
Concerns Related to PEGylation Anti-PEG Antibody.pdf - page 3/3

Related documents

potential drawbacks of pegylated therapeutic proteins
pegylation reagents
untitled pdf document
untitled pdf document 1
creative pegworks
cleavable vs non cleavable linkers in antibody drug conjugates

Related keywords